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Abstract
Background: Cytochrome P450 oxidoreductase deficiency (PORD) is a rare disease exhibiting a variety of clinical
manifestations. It can be difficult to differentiate with other diseases such as 21-hydroxylase deficiency (21-OHD),
polycystic ovary syndrome (PCOS) and Antley–Bixler syndrome (ABS). Nearly 100 cases of PORD have been reported
worldwide. However, the genetic characters and clinical management are still unclear, especially in China.
Case presentation: In this study, we report a 27-year-old female Chinese patient who first presented with
amenorrhea and recurrence of large ovary cyst. She was misdiagnosed with PCOS and non-classical 21-OHD due to
ovary cysts and elevated 17-hydroxy-progesterone. The patient’s complaining of a mild difficulty of bending the
metacarpophalangeal joints reminded us to consider PORD, which usually presents with skeletal deformities and
sexual dysfunction. The diagnosis of PORD was confirmed by genetic analyses, which showed the patient harboring
a homozygous missense mutation in the POR gene (R457H) and her parents carrying the heterozygous mutation.
The patient was treated with low-dose corticosteroids and estrogen/progesterone sequential therapy, and her
ovarian cyst gradually reduced with regular menstruation in the follow-up. Moreover, the clinical and genetic
characteristics of 104 previously reported PORD cases were also summarized and analyzed.
Conclusions: PORD is a very rare disease which can be easily misdiagnosed in mild cases. Clinicians should keep in
mind of this disease in patients with sexual dysfunction, especially combined with special skeletal deformities. Our
data could provide a consciously understanding of this disease for clinic practicers. Low-dose corticosteroids
combined with estrogen/progesterone sequential therapy will be effective in PORD patients with recurrence of
large ovary cyst. The fact that the reported PORD patients in China carrying an identical variant R457H in POR gene
also give us a viewpoint that R457H mutation in POR gene maybe important in causing PORD in Chinese as same
as in Japanese.
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Background
Cytochrome P450 oxidoreductase (POR) is encoded by
the POR gene. POR transfers electrons from NADPH to
cytochrome P450 enzymes for drug and toxin metabolism
as well as steroid hormone synthesis (Fig. 1) [1]. Since
P450 enzymes are involved in the catalysis of many
substrates, POR deficiency (PORD) (OMIM: 613571 and
OMIM: 201750) can lead to disorders of steroid hormone,
drug and toxin metabolism, to various extents. PORD
resulting from mutations in the POR gene has been re-
ported by different teams since 2004 [2–6]. Currently,
nearly 100 cases have been reported worldwide (Table 1).
However, the treatment method of this rare disease is not
clear due to the limited number of patients.
PORD can cause reduced activities of multiple en-
zymes participating in the synthesis of both adrenal and
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gonadal steroid hormones, which further leads to the
dysfunction of the sex hormones and a decrease in glu-
cocorticoids. Therefore, the disease is a type of special
congenital adrenal hyperplasia (CAH). PORD is very rare
and exhibits a variety of clinical manifestations, such as
oligomenorrhea and ovarian cysts which resemble poly-
cystic ovary syndrome (PCOS), elevated 17-hydroxy-
progesterone (17OHP) which resembles 21-hydroxylase
deficiency (21-OHD), and skeletal deformities which re-
semble Antley–Bixler syndrome (ABS). Therefore, in
some cases, it can be difficult to differentiate PORD
from PCOS, 21-OHD and ABS. However, PORD usually
doesn’t exhibit hyperandrogenism which differs from
PCOS and 21-OHD. In this study, we report a female
adult Chinese PORD case who was misdiagnosed many
times, and analyze the clinical presentation and genetic
character of the patient and her parents.
Case presentation
Patient characteristics
A 27-year-old female (46,XX) patient with normal cogni-
tion visited the Endocrinology Clinic of 1st affiliated hos-
pital of China Medical University (Shenyang) for
amenorrhea with an unknown etiology. The patient had
labial fusion when she was born and underwent plastic
surgery afterward. During puberty, the patient under-
went another surgery for an ovarian cyst. The patient
was treated in another hospital as PCOS for several
times resulting with mild remission of amenorrhea and
recurrence of ovarian cysts. The patient was suspected
of having 21-OHD due to increased 17OHP levels and
came to our hospital for a genetic test for CYP21A2 mu-
tations. The patient did not have fatigue, loss of appetite
or other symptoms and was the only child in the family.
Her parents appeared to be normal. She was born by va-
ginal delivery, and the mother had no complaints of ab-
normal manifestations during the perinatal period or
history of reproductive system diseases. Her parents are
nonconsanguineous. Physical examination of the patient
revealed the following characteristics: a height of 165 cm
and weight of 55 kg; no hyperandrogenism symptoms
like hirsutism or acne; and no purple stripes. The patient
complained of difficulty of bending the metacarpopha-
langeal joints from childhood (Fig. 2a-c). There were no
obvious abnormalities in the genitals.
Clinical examination and testing
The ultrasound showed the presence of a 1.2 × 1.4 cm
fluid area in the left ovary, and there was a 9.5 × 6.3 ×
4.3 cm cyst in the right ovary behind the uterus. Digital
radiography (DR) suggested there were no bone abnor-
malities (Fig. 2d). The adrenal CT scan showed there were
no obvious hyperplasia changes (Fig. 2e). The laboratory
test results of the patient and her parents are shown in
Table 1. The levels of progesterone and 17-hydroxy pro-
gesterone of the patient were significantly increased. An-
drogen levels were not increased, and the basal level of
cortisol in the morning was within the lower limit of the
normal level. Cortisol was stimulated by the ACTH stimu-
lation test. There were no abnormalities in the other mea-
surements or in those of the parents.
Gene testing
CYP21A2 (NM_000500) was tested first due to the sus-
picion of 21-OHD, but no mutations were found in the
patient. Then the patient’s complaint about a mild diffi-
culty of bending the metacarpophalangeal joints
reminded us to consider PORD, which usually presents
Fig. 1 POR involvement in various biological pathways. POR donates electrons to all P450 enzymes, and at the same time, provides electrons for
some proteins and small molecules, which involved in numerous biological activities such as biosynthesis, cholesterol metabolism, sex hormone
metabolism and the metabolism of drugs and toxins
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with skeletal deformities and sexual dysfunction, so
POR (NM_000941) gene was tested secondly. Exon
11 of PORharbored a homozygous mutation
(c.1370G > A) which leads to a conversion of argin-
ine at amino acid position 457 to histidine (R457H).
The patient’s parents were both heterozygous car-
riers of this variant (Fig. 3). Since the disease-
causing homozygous mutations in POR gene were
found, no further genetic analysis was performed.
Treatment and follow up
Our patient once underwent surgery to remove a large
ovarian cyst; however, since the diagnosis was unclear
and hormone replacement therapy was not given, the
ovarian cyst soon recurred. The patient was given low-
dose corticosteroids twice a day (hydrocortisone 5 mg in
the morning and 2.5 mg in the afternoon) and estrogen/
progesterone sequential therapy in our hospital, and her
ovarian cysts gradually decreased in size (the biggest
Fig. 3 POR gene testing results of the patient and her parents. Exon 11 of POR harbored a homozygous mutation (c.1370G > A) which leads to a
conversion of arginine at amino acid position 457 to histidine (R457H). The patient’s parents were both heterozygous carriers of this variant
Fig. 2 The appearance of the hands of the patient, hand DR and adrenal CT scans. a-c shows patient’s difficulty of bending the
metacarpophalangeal joints, however her hand DR (d) suggested there were no bone abnormalities. The adrenal CT scan (e) showed there were
no obvious hyperplasia changes
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ovarian cyst shrank to 3.5 × 3.3 × 2.3 cm) with regular
menstruation in the following visits. The serum levels of
ACTH, LH, 17OHP and P were declined accordingly
(Table 2). No adverse effect of corticosteroids was found
in the follow-up.
Discussion
PORD is a rare variant of CAH disease. As early as
1985, a CAH case which had characteristics of both 21-
OHD and 17α-hydroxylase deficiency (17-OHD) was re-
ported; however, no mutations were found in the patient
in CYP21A2 or CYP17A1, two genes known to underlie
these diseases [7]. In 2004, Fluck et al. reported that this
new CAH disease was caused by a mutation in the POR
gene, and they also showed that the mutation of POR
could lead to a decrease in the activity of P450 enzymes
including CYP21A2, CYP17A1 and CYP19A1 [6]. POR
donates electrons to all P450 enzymes, and at the same
time, provides electrons for some proteins and small
molecules (Fig. 1). POR plays an important role in bio-
logical activities such as biosynthesis, cholesterol metab-
olism, sex hormone metabolism and the metabolism of
drugs and toxins. In addition, the loss of POR enzyme
activity varies with POR mutation type; thereby, PORD
has a variety of clinical manifestations from menstrual
disorders to severe hermaphroditism and skeletal mal-
formations, and even fetal death. At present, around 100
PORD cases have been reported worldwide (Table 1).
The proportion of female and male cases is roughly
equal (54:46). Most of the reported patients are of Japa-
nese or European descent (38:46). The majority are new-
born or fetal cases (76%), and adults account for 24%
reported cases. The primary clinical manifestations in-
clude abnormal hormone levels at birth or developmen-
tal delay after puberty (89.2%), hermaphroditism (75%),
maternal virilization (40.8%), ABS-like skeletal abnor-
malities (82.7%), underlying adrenal insufficiency (74.6%)
and ovary cysts in females (46.7%). Clinicians should al-
ways keep in mind of this disease in patients with sexual
dysfunction, especially combined with special skeletal
deformities.
Most of PORD patients presented with ambiguous
genitalia (75%). The pathogenic mechanisms of this
manifestation are associated with impaired syntheses of
testosterone, dihydrotestosterone and conversions of the
androgens to estrogens. These syntheses and conver-
sions depend on CYP17A1, CYP19A1, CYP21A2, which
require POR [8, 9]. In addition, maternal virilization
(40.8%) is described in mothers during pregnancies of
PORD fetus, and it is also due to placental aromatase
(CYP19A1) deficiency [10].
Similar to 21-OHD, despite that the basal levels of
ACTH and cortisol are generally normal in PORD pa-
tients, the ACTH stimulation test showed that most of
Table 2 Test results of the patient and her parents
Father Mother Patient (46, XX)
Baseline 3 months after treatment 6 months after treatment
age (y) 55 54 27
FT (pmol/L) 116.00 (55.05–183.50) 6.42 (0.77–33.03) 6.10 (0.77–33.03) – 5.38
SHBG (nmol/L) 9.00 (13.00–71.00) 48.50 (18.00–114.00) 80 (18.00–114.00) – 78
T (nmol/L) 27.70 (9.08–55.23) <0.69 (0.69–2.15) <0.69 (0.69–2.77) – <0.69
AND (nmol/L) 4.76 (1.05–11.52) 1.53 (2.09–10.82) <1.05 (2.09–10.82) – <1.05
DHEA (umol/L) 1.70 (2.17–15.20) 1.95 (0.95–11.67) 0.76 (0.95–11.67) – 0.82
E2 (pmol/L) 117.0 (73.4–206.0) 106.0 (73.4–110.0) 244.0 (73.4–587.0) 225 231
P (nmol/L) 1.17 (0.86–2.90) <0.64 (0.64–3.20) 8.68 (0.64–3.60) 4.61 3.83
17OHP (ng/mL)
Baseline 0.80 (0.50–2.10) 1.20 (0.13–0.51) 9.60 (0.10–0.80) 3.8 3.1
60 min after 25U ACTH iv – – >20 – –
LH (mIU/mL) 7.76 (0.80–7.60) 50.60 (11.3–398.00) 4.78 (1.10–11.60) 2.72 2.73
FSH (mIU/mL) 12.30 (0.70–11.10) 92.90 (21.70–153.00) 7.14 (2.80–11.30) 6.40 6.18
PRL (mIU/mL) 119.0 (40.0–530.0) 111.0 (40.0–530.0) 443.0 (40.0–530.0) – 383.2
ACTH (pg/ml) 48.71 (7.20–63.30) 10.77 (7.20–63.30) 48.75 (7.20–63.30) 33.48 14.52
COR (nmol/L)
Baseline 497.8 (171.0–536.0) 244.1 (171.0–536.0) 198.5 (171.0–536.0) 466.5 303.3
60 min after 25U ACTH iv – – 642.3 – –
T testosterone, FT free testosterone, AND androstendione, SHBG sex-hormone binding globulin, DHEA dehydroepiandrosterone, E2 estradiol, ACTH adrenocortico-
tropic hormone, COR cortisol, LH luteinizing hormone, FSH follicle-stimulating hormone, PRL prolactin, 17OHP 17-hydroxyprogesterone, P progesterone
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the patients (74.6%) have insufficient adrenocortical re-
serve. Activities of different POR mutants for target en-
zymes would have a certain role in variability of
adrenocortical insufficiency [11–13]. Patients with insuf-
ficient adrenocortical reserve may need long-term gluco-
corticoid replacement therapy [14], especially during
disease, inflammation, stress or surgery. Mineralocortic-
oid dysfunction is not apparent in PORD patients. How-
ever, PORD patients who are homozygous for an A287P
mutation have been found to have increased blood pres-
sure (caused by an increase in deoxycorticosterone),
which is similar to that seen in 17-OHD [15]. Thus,
regular blood pressure monitoring is required for PORD
patients.
Ovarian cysts were found in this patient and in other
adult female patients (46.7%). If patients have a history of
amenorrhea or anovulation, the disease is easily misdiag-
nosed as PCOS at primary medical units. The decrease in
estrogen causes hypergonadotropic hypogonadism, which
stimulates the growth of the ovaries. On the other hand,
mutations in POR lead to the reduced activity of
CYP51A1, thus reducing the synthesis of meiosis-
activating sterol and further inducing a dysfunction in
meiosis and the maturation of the oocytes. Under the
above-mentioned “double hit”, compared with ovarian
cysts associated with other hormone synthesis disorders,
those in PORD are more difficult to control. Surgical
treatment combined with corticosteroid and sex hormone
replacement therapy is often required to prevent recur-
rence [14]. Our patient responded well to this therapy
during follow-up.
Another important clinical feature of PORD is that
there are different degrees of Antley-Bixler syndrome-
like skeletal deformities (82.7%). Skeletal deformities in-
clude midface hypoplasia, craniosynostosis, foot and
hand deformity, bony union of the large joints and
femur bending. Some researchers have attempted to
quantify these skeletal deformities and assess the severity
according to quantitative indices. They found that com-
pound heterozygous and homozygous mutations in the
POR gene are associated with more serious skeletal de-
formities. This may also result from the effect of various
mutations on the activity of related enzymes [16]. Our
patient harbored a homozygous mutation but only had
mild metacarpophalangeal joint contracture, which is
not a typical skeletal deformity, showing the heterogen-
eity of this symptom in PORD. The pathogenic mecha-
nisms of PORD-associated skeletal deformities may be
associated with lanosterol 14α demethylase (CYP51A1)
which involved in cholesterol biosynthesis [17] and ret-
inoic acid which metabolized by microsomal CYP26 pro-
teins [18].
P450 liver enzymes and heme oxygenase involving in
drug metabolism need POR to provide electrons,
therefore, the mutation of POR gene or associated SNPs
may affect drug metabolism in human body [19, 20] and
affect the progression of some diseases such as malaria
and sepsis [21]. For example, the R457H mutation in this
patient can inactivate the P450 enzymes including
CYP1A2, CYP2C19, CYP2D6 and CYP3A4 which are
important for drug metabolism [12, 22, 23]. Thus, there
may be possible risks if the PORD patients are adminis-
tered medications metabolized by these enzymes.
It has been reported that there are nearly 200 POR mu-
tations and single nucleotide polymorphisms (SNPs) [24],
including more than 60 missense mutations (http://
www.cypalleles.ki.se/por.htm). According to the cases re-
ported in the literature, the most common mutation type in
the Japanese population is R457H (51/78, 65.4%), and it is
A287P (39/92, 42.4%) in Europeans [6, 11, 13, 16, 25–33],
which shows significant ethnic differences. R457H was once
thought to be a founder mutation in Japan [34], but this
mutation has also been reported in Europeans and other
ethnicity [35]. There are few PORD case reports in China.
By searching the literature published in Chinese, we found
that only two PORD cases have been reported, and both
cases were compound heterozygous carriers including
R457H. The patient we report here is the third Chinese
PORD patient to be described, and she is homozygous for
R457H, with parents who are heterozygous, nonconsan-
guineous carriers. These genetic characters suggest R457H
maybe common in the Chinese PORD patients, which are
similar with Japanese.
Conclusions
In conclusion, PORD is a very rare disease which can be
easily misdiagnosed in mild cases. Clinicians should keep
in mind of this disease in patients with sexual dysfunction,
especially combined with special skeletal deformities. Our
data could provide a consciously understanding of this
disease for clinic practicers. Low-dose corticosteroids
combined with estrogen/progesterone sequential therapy
will be effective in PORD patients with recurrence of large
ovary cyst. The fact that the reported PORD patients in
China carrying an identical variant R457H in POR gene
also give us a viewpoint that R457H mutation in POR
gene maybe also important in causing PORD in Chinese,
which is similar with Japanese.
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